← Back to Search

Cognitive Remediation

Cognitive Enhancement Therapy for Autism (PerspectivesII Trial)

N/A
Waitlist Available
Led By Nancy J Minshew, Ph.D.
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 16-45 years
Be younger than 65 years old
Must not have
Comorbid attention deficit hyperactivity disorder (ADHD) that is untreated
IQ < 80
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 9, 18, and 30 months
Awards & highlights

Summary

This trial will test two therapies for adults with autism. One therapy aims to improve thinking and planning through mental exercises. The other provides support to help manage emotions and social skills. The study focuses on adults because there are few treatments available for them.

Who is the study for?
Adults aged 16-45 with autism, Asperger's syndrome, or pervasive developmental disorder not otherwise specified (NOS), who have an IQ over 80 and significant social/cognitive challenges. Participants must speak English fluently, be able to attend sessions in Pittsburgh, PA, and have a supportive person for information sharing.
What is being tested?
The trial is testing Cognitive Enhancement Therapy (CET) against Enriched Supportive Therapy (EST). CET focuses on improving thinking and social skills while EST helps with understanding the condition, managing emotions/stress, enhancing social abilities, and problem-solving.
What are the potential side effects?
Since both interventions are psychological therapies rather than medications, they may cause emotional discomfort or distress. There might also be temporary increases in anxiety as participants work through personal challenges during therapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 16 and 45 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have ADHD that has not been treated.
Select...
My IQ is below 80.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 9, 18, and 30 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 9, 18, and 30 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Neurocognition
Change in Social cognition
Secondary study objectives
Change in Functional outcome
Other study objectives
Change in Processing Speed/Attention

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Cognitive Enhancement TherapyExperimental Treatment1 Intervention
This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful. Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only
Group II: Enriched Supportive TherapyActive Control1 Intervention
This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies. Time commitment: about 1 hour per week; Location: Pittsburgh, PA only
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Enhancement Therapy
2012
N/A
~160

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Cognitive Enhancement Therapy (CET) and similar cognitive remediation interventions aim to improve cognitive functions such as thinking, planning, and socialization in individuals with Autism Spectrum Disorder (ASD). These therapies typically involve structured tasks that target specific cognitive deficits, such as working memory and executive functioning, through repeated practice and gradual increase in task complexity. The importance of these treatments lies in their potential to enhance daily functioning and social interactions for ASD patients, thereby improving their overall quality of life and ability to integrate into various social and occupational settings.
Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.Neural Mechanisms of Qigong Sensory Training Massage for Children With Autism Spectrum Disorder: A Feasibility Study.Pivotal response treatment for preschoolers with autism spectrum disorder: Defining a predictor profile.

Find a Location

Who is running the clinical trial?

National Institute of Mental Health (NIMH)NIH
2,869 Previous Clinical Trials
2,777,450 Total Patients Enrolled
83 Trials studying Autism Spectrum Disorder
40,511 Patients Enrolled for Autism Spectrum Disorder
University of PittsburghLead Sponsor
1,762 Previous Clinical Trials
16,347,917 Total Patients Enrolled
15 Trials studying Autism Spectrum Disorder
10,438 Patients Enrolled for Autism Spectrum Disorder
Nancy J Minshew, Ph.D.Principal InvestigatorUniversity of Pittsburgh

Media Library

Cognitive Enhancement Therapy (Cognitive Remediation) Clinical Trial Eligibility Overview. Trial Name: NCT03170453 — N/A
Autism Spectrum Disorder Research Study Groups: Enriched Supportive Therapy, Cognitive Enhancement Therapy
Autism Spectrum Disorder Clinical Trial 2023: Cognitive Enhancement Therapy Highlights & Side Effects. Trial Name: NCT03170453 — N/A
Cognitive Enhancement Therapy (Cognitive Remediation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03170453 — N/A
~8 spots leftby Sep 2025